Dupilumab and lymphoma risk in asthma

<title>Extract</title> We read with interest the recent article by M<sc>a</sc> <italic>et al</italic>. [1], which investigated the association between dupilumab and lymphoma risk in asthma using a population-based cohort study. The authors should be commended for applying a large US dataset and a target trial emulation framework to address an important question in pharmacovigilance of biologic therapies. However, we urge caution in interpreting the findings, particularly the reported increased risk of lymphoma among patients treated with dupilumab.